BioAtla is a clinical-stage biopharmaceutical company developing its antibody-based therapeutics for the treatment of solid tumor cancer. Co.'s conditionally active biologics (CAB) capitalize on its proprietary discoveries with respect to tumor biology, enabling Co. to target known and validated tumor antigens. Co.'s CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic and has designed its antibodies to selectively bind to their targets on cancer cells under acidic pH conditions but not on targets in normal tissues. The BCAB average annual return since 2020 is shown above.
The Average Annual Return on the BCAB average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BCAB average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BCAB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|